The β-blocker heart attack trial: studies of platelets and factor VIII

D. Green*, E. C. Rossi, O. Haring

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Serial studies of platelets and factor VIII were performed in 16 patients enrolled in the Beta Blocker Heart Attack Trial. Eight patients received placebo, and eight were treated with propranolol, in doses ranging from 40 to 320 mg per day for periods of from 6 to 31 months. No differences in platelet-collagen affinity, factor VIII coagulant activity, factor VIII related antigen, or ristocetin cofactor activity were observed between treated and untreated patients. However, circulating platelet aggregates, which were initially increased in both groups, significantly declined in those receiving propranolol (p < 0.05). This indicates that customarily used doses of propranolol affect platelet reactivity in vivo.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalThrombosis Research
Issue number2
StatePublished - Oct 15 1982


  • Factor VIII
  • Platelet Aggregates
  • Propranolol
  • β-Blocker

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The β-blocker heart attack trial: studies of platelets and factor VIII'. Together they form a unique fingerprint.

Cite this